RaySearch Laboratories ABRSLBF +0.81%92 Altman Z-Score is 5.97 as of Jul. 03, 2026, which is 21% above its 10-year median of 4.92. GuruFocus rates RSLBF with a GF Score™ of 92/100 and a GF Value™ of $20.80 (Fairly Valued). The stock has 2 warning signs investors should review. Among 660 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks better than 80.76% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 5.92 is strong.
RaySearch Laboratories AB has a Altman Z-Score of 5.97, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for RaySearch Laboratories AB's Altman Z-Score or its related term are showing as below:
RSLBF'
s Altman Z-Score Range Over the Past 10 Years
Min: 1.3 Med: 4.92 Max: 22.47
Current: 5.92
During the past 13 years, RaySearch Laboratories AB's highest Altman Z-Score was 22.47. The lowest was 1.30. And the median was 4.92.
RaySearch Laboratories AB (OTCPK:RSLBF) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RSLBF vs VEEV, BTSG, TEM: Altman Z-Score Comparison
For the Health Information Services subindustry, RaySearch Laboratories AB's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB Altman Z-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's Altman Z-Score falls into.
RaySearch Laboratories AB Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
RaySearch Laboratories AB (RSLBF) has a Altman Z-Score of 5.97 as of Jul. 03, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on RaySearch Laboratories AB and its competitors. This is 21% above median its historical median of 4.92. Over the past decade, RaySearch Laboratories AB's Altman Z-Score has ranged from 1.30 to 22.47. According to the industry distribution chart, RaySearch Laboratories AB ranks #127 out of 660 companies in the Healthcare Providers & Services industry, placing it in the top 19.2%.
Is RaySearch Laboratories AB's Altman Z-Score too high?
RaySearch Laboratories AB's current Altman Z-Score of 5.97 is 21% above median its 10-year median of 4.92. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 22.47. The Healthcare Providers & Services industry median Altman Z-Score is 2.44. RaySearch Laboratories AB's value of 5.97 is 144.7% above this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #127 out of 660 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, RaySearch Laboratories AB has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Altman Z-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #127 out of 660 companies for Altman Z-Score. This places RaySearch Laboratories AB in the top 19% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.44. RaySearch Laboratories AB's value of 5.97 is 144.7% above this benchmark. Historically, RaySearch Laboratories AB's own Altman Z-Score has ranged from 1.30 to 22.47 over the past decade. While the company's 10-year median is 4.92 vs. the industry median of 2.44, RaySearch Laboratories AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Healthcare Providers & Services company?
The median Altman Z-Score among Healthcare Providers & Services companies is 2.44, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current Altman Z-Score of 5.97 is 144.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median Altman Z-Score is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current Altman Z-Score is 5.97, which is 21% above median its own 10-year median of 4.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (RSLBF) is currently considered Fairly Valued. The stock's GF Value™ is $20.80, compared to a current price of $21.17 — trading 1.8% above its estimated fair value. The current Altman Z-Score is 5.97, which is 21% above median its 10-year median of 4.92 and 144.7% above the Healthcare Providers & Services industry median of 2.44. RaySearch Laboratories AB's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For RaySearch Laboratories AB (RSLBF), the current Altman Z-Score is 5.97 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (RSLBF) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of $21.17 is trading 1.8% above its estimated GF Value™ of $20.80.
GuruFocus considers RaySearch Laboratories AB to be Fairly Valued.
Key valuation signals for RSLBF:
Altman Z-Score: 5.97 (21% above median its 10-year median of 4.92)
GF Value™: $20.80 vs. price of $21.17 (1.8% above fair value)
Industry Position: 144.7% above the Healthcare Providers & Services median (#127 of 660)
No single metric tells the full story. See the RSLBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
92GF Score
Get the complete analysis for RSLBF
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RSLBF has been successfully added to your 
